Aim: To identify a key protein that binds monomeric g protein RhoA and activates the RhoA/Rho kinase/MYPT1 axis in vascular smooth muscle cells (VSMCs) upon angiotensin II (Ang II) stimulation. Methods: Primary cultured VSMCs from Sprague-Dawley rats were transfected with siRnAs against leukemia-associated RhogeF (LARg), and then treated with Ang II, losartan, PD123319, or Val 5 -Ang II. The target mRnA and protein levels were determined using qPCR and Western blot analysis, respectively. Rat aortic rings were isolated, and the isometric contraction was measured with a force transducer and recorder. Results: Stimulation with Ang II (0.1 µmol/L) for 0.5 h significantly increased the level of LARG mRNA in VSMCs. At 3, 6, and 9 h after the treatment with Ang II (0.1 µmol/L) plus AT 2 antagonist PD123319 (1 µmol/L) or with AT 1 agonist Val 5 -Ang II (1 µmol/L), the LARG protein, RhoA activity, and phosphorylation level of myosin phosphatase target subunit 1 (MYPT1) in VSMCs were significantly increased. Knockdown of LARg with siRnA reduced these effects caused by AT 1 receptor activation. In rat aortic rings pretreated with LARg siRnA, Ang II-induced contraction was diminished. Conclusion: Ang II upregulates LARg gene expression and activates the LARg/RhoA/MYPT1 axis via AT 1 , thereby maintaining vascular tone.
Introduction
Angiotensin II (Ang II) plays a pivotal role in blood pressure regulation. Activation of Ang II receptors, which increases free intracellular Ca 2+ concentrations and increases myosin light chain (MLC) kinase activity, can cause vessel constriction. These events result in MLC phosphorylation and subsequent smooth muscle contraction [1] [2] [3] [4] . However, a portion of the agonist-induced smooth muscle contraction, termed Ca 2+ sensitization, is mediated by the Ca 2+ -independent activation of monomeric G protein RhoA and the downstream target Rho-kinase [4, 5] . RhoA activity is regulated by Rho guanine nucleotide exchange factors (RhoGEFs) and Rho GDP dissociation inhibitors [6] [7] [8] [9] . Despite RhoA's requirement of basal activity for homeostatic functions under physiological conditions, sustained-and over-activation of RhoA may result in pathological effects, including long-lasting contractions in vascular smooth muscle cells (VSMCs) [10] . A link between Ang II type 1 receptors (AT 1 ) and the RhoA/ Rho kinase pathway has been reported [4, 11] . Three RhoGEFs may link AT 1 to RhoA activation: PSD-95/Disc-large/ZO-1 homology (PDZ)-RhoGEF, leukemia-associated RhoGEF (LARG), and p115-RhoGEF [4, 12, 13] . It has been reported that Ang II transiently upregulates the expression of LARG mRNA and protein, but not PDZ-RhoGEF or p115-RhoGEF in a rat VSMC model [14] . A later study also found that the overexpression of PDZ-RhoGEF, but not LARG or p115-RhoGEF, enhances Ang II-stimulated RhoA activity, and the knockdown of PDZ-RhoGEF decreases Ang II-stimulated RhoA activity in VSMCs [15] . Dubash et al showed that the knockdown of both p115-RhoGEF and LARG significantly decreased both RhoA activation and the formation of stress fibers and also decreased focal adhesions downstream of fibronectin adhesions [16] . Wirth et al established the role of LARG in physiological responses to Ang II stimulation by showing that arteries in LARG knockout mice produce a reduced maximum degree of contraction in response to Ang II and fail to develop deoxycorticosterone acetate plus NaCl (DOCA/salt)-induced hypertension [17] . Another study reported that p115-RhoGEF is responsible for AT 1 -mediated RhoA activation and that ablation of the p115-RhoGEF gene in VSMCs prevents Ang II-induced hypertension [8] . All of these previous results are inconsistent with RhoGEF playing a primary role in the regulation of RhoA/Rho-kinase.
Rho-kinase is a divergent point for multiple signals in the RhoA/Rho-kinase pathway for the regulation of smooth muscle cell function. Rho-kinase increases MLC phosphorylation via the phosphorylation of myosin phosphatase target subunit 1 (MYPT1) on MLCP. Therefore, MYPT1 may play a critical role in the Ca 2+ sensitization of myofilaments and in maintaining vascular smooth muscle tension under constant Ca 2+ concentration. Nevertheless, the role of LARG gene expression in MYPT1 phosphorylation and Ca 2+ sensitization of VSMCs is not yet understood.
The objective of this study was to identify a specific molecule(s) that activates RhoA in response to stimulation by an AT 1 agonist in primary cultured VSMCs. Additionally, we investigated the association between LARG gene expression and the extent of MYPT1 phosphorylation in VSMCs after AT 1 receptor activation. Finally, we used LARG siRNA knockdown to study aortic ring contractile forces ex vivo.
Materials and methods

Cell culture
Sprague-Dawley (SD) rat aorta smooth muscle cells (RAOSMC) 6 were obtained from the tunica intima and the inner layer of tunica media of healthy and fibrous plaque-free rat aorta. The cells were cultured in M199 culture medium, supplemented with 20% fetal bovine serum 10 , penicillin (100 U/mL), and streptomycin (100 µg/mL) at 37 °C in a humidified atmosphere of 95% air and 5% CO 2 . The cells were passaged twice a week by harvesting with trypsin and seeding at a 1:4 ratio into 100-mm dishes. The cells from passage two through passage five were used in all of the experiments. The cells were harvested at the indicated times and used for qPCR or Western blot analysis.
Isolation of total RNA and reverse transcription RNA from the cultured cells was isolated using the TRIzol reagent 10 . All reverse-transcriptase reactions were performed using a High-Capacity cDNA Reverse Transcription kit according to the manufacturer's instructions 2 . The cDNA was used immediately for qPCR or stored at -80 °C.
qPCR assay
We performed the qPCR assays using a 7000 Real-time PCR Sequence Detection System [2] . The cDNA generated from total RNA (30 ng) was used for each reaction. The amount of each target mRNA relative to the internal normalization control, GAPDH, was calculated using the Comparative C t method as follows:
target mRNA exp /target mRNA con =2
−∆∆Ct
Where, ∆∆C t =∆C t, exp -∆C t, con =(C t, target mRNA -C t, GAPDH ) exp -(C t, target mRNA -C t, GAPDH ) con ∆C t, exp (the change in cycle threshold) is the target mRNA's C t value in the experimental group (target gene; treated duration of 0.5, 3, or 6 h), and ∆C t, con is the C t value of the target mRNA in the control group (target gene; 0 h; non-stimulated conditions).
Preparation of cell extracts and Western blot analysis
To prepare whole-cell lysates and to measure membrane translocation of RhoA (activation of RhoA), culture dishes were cooled on ice and washed twice with ice-cold phosphatebuffered saline (PBS). All procedures were performed on ice. Lysis buffer for whole-cell lysates For whole-cell lysate preparation, the samples were sonicated for 5 s and then centrifuged at 12 000×g for 15 min at 4 °C. The supernatant was transferred to a new tube and kept on ice. For RhoA translocation detection, the samples were centrifuged at 500×g for 10 min at 4 °C to remove the nuclei. The membrane and cytosolic fractions were further separated by centrifugation at 100 000×g for 1 h at 4 °C 4 . The supernatant (cytoplasmic fraction) was kept on ice, and the pellet (membrane fraction) was resuspended in PBS buffer containing Tris-HCl, 100 mmol/L NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 2 mmol/L EDTA, 2 mmol/L PMSF, and 0.8 µg/mL leupeptin. The protein concentration was determined using a BSA Protein Assay kit 13 . Protein (40 µg) was separated by electrophoresis on a 12% or 6% polyacrylamide gel and transferred to a polyvinylidene difluoride membrane. Nonspecific binding sites were blocked using Protein-Free Blocking Buffers 13 for 1 h at 24 °C. The membranes were then incubated overnight at 4 °C with the following antibodies: anti-RhoA (1:1000) 14 , anti-flotillin-2 (1: 1000) 14 , anti-LARG (1:1000) 14 , anti-phospho-MYPT1 (Thr 696 ) (1:2000) 11 , anti-total-MYPT1 (1:2000) 5 , anti-tubulin (1:2000) 14 , or anti-GAPDH (1:1000) 7 . Following exposure to a horseradish peroxidase-conjugated secondary anti-mouse, anti-rabbit, or anti-goat antibody, the membrane was subjected to the ECL reagent 11 and exposed to film [18] . The bands were quantified using AlphaImage software 3 .
Rho GTPase activity assay RhoA activity was determined using an absorbance based , according to the manufacturer's instructions [15] . This assay employs a Rho-GTP binding protein, which coats the wells of a 96-well plate. Active, GTP-bound Rho in the cell lysates will bind to the wells, while inactive GDP-bound Rho is removed in the washing steps. The bound active RhoA is detected by incubation with a specific RhoA antibody followed by an HRPconjugated secondary antibody and a detection reagent, after which the absorbance is read on a SpectraMax M5 Microplate Reader 12 . Primary VSMCs were cultured in 100-mm dishes and treated as indicated above. Proteins were harvested by incubating the cell with the provided cell lysis buffer with protease inhibitors and centrifugating at 12 000×g at 4 °C for 2 min to remove cell debris. The protein concentration was determined according to the manufacturer's protocol, and the cell extracts were equalized to a protein concentration of 1.5 mg/mL for assay. Absorbance was detected according to the manufacturer's recommendation after a 45-min incubation at room temperature with the primary anti-RhoA antibody [19] .
siRNA experiments Scrambled siRNA (5 nmol/L) or siRNA against LARG (5 nmol/L) was introduced into the VSMCs using the siPORT TM NeoFX TM Transfection Agent (Cat#AM4511) 1 . LARG siRNA 1 (Cat#4390771) sequences were as follows: sense, 5'-GCAUCGAUCUGUAUACACUtt-3', and antisense, 5'-AGUGUAUACAGAUCGAUGCtt-3'; the scrambled siRNA (Cat#4390843) was an siRNA sequence not homologous to any known gene 1 . After transfection for 36 h, the cells were treated with Ang II, losartan, PD123319, or Val 5 -Ang II, which were dissolved in distilled water. Cells were harvested at the indicated times and used for qPCR or Western blot analysis.
Tissue preparation and isometric force recording All animal procedures were performed in accordance with the Institutional Animal Care and Use Committee of National Taiwan University College of Medicine (Approval No 20090097). Male SD rats (275-300 g) were purchased from the National Laboratory Animal Centre of Taiwan, China. The rats were anesthetized with sodium pentobarbital (50 mg/kg, ip), and the thoracic aorta was excised and cleaned of adventitial tissue using a physiological saline solution (Krebs-Henseleit solution, KHS, pH 7.4). The aortas were cut into 3 mm rings, and the endothelia were removed.
The rings were incubated in culture medium containing either an siRNA against LARG (10 nmol/L) or scrambled siRNA (10 nmol/L) for 48 h at 37 °C [20, 21] . The siRNA was introduced using the siPORT TM NeoFX TM Transfection Agent. After incubation, the aortic rings were mounted in myograph organ baths containing KHS at 37 °C and gassed with 95% O 2 and 5% CO 2 . The isometric force generation was recorded with a force transducer (TypeBG25) and recorder (RS 3400) 9 . The rings were placed under 15 mN tension and equilibrated for 120 min. During this period, KHS was refreshed every 30 min, and the rings were re-stretched as necessary to maintain 15 mN tension. After equilibration, the rings were contracted using phenylephrine (PE, 0.1 µmol/L). Acetylcholine (ACh, 1 µmol/L) was added during the contraction plateau phase to verify the efficient disruption of the endothelium. The drugs and reagents were washed out until the contractile response returned to baseline levels. We then recorded the contractile response curves for Ang II, losartan, and PD123319, which were dissolved in distilled water [22, 23] .
Statistical analysis
The data are expressed as the mean±SD, and n represents the number of independent experiments. A t-test, ANOVA and the post-hoc test (Tukey) were employed to analyze the results.
A P-value of less than 0.05 was considered significant. All statistical analyses were performed using SPSS19.0 15 . LARG is induced by Ang II through AT 1 The activation of AT 1 , by the agonist Val 5 -Ang II (Val5) (1 µmol/L), significantly induced LARG protein expression (n=6) after a 3 h drug treatment (Figure 2A ). Ang II (0.1 µmol/L) plus PD123319 (1 µmol/L), an AT 2 antagonist, also increased LARG protein levels (n=6) after the 3 h treatment ( Figure 2B ). The elevation in LARG protein levels after AT 1 activation was maintained for 9 h (Figure 2A, 2B) . Losartan (1 µmol/L), an AT 1 antagonist, prevented Ang II stimulated LARG expression (n=6) ( Figure 2C ). [24, 25] . RhoA activation is described by the ratio of RhoA in the particulate versus that in the soluble fraction. VSMCs were stimulated with Val5 (1 µmol/L) for 3, 6, or 9 h. Figure 3A shows that RhoA activity continuously increased over 9 h (n=6), while Figure 3B shows that RhoA activity was also enhanced following treatment with Ang II (0.1 µmol/L) plus PD123319 (1 µmol/L) (n=6). Treatment with losartan (1 µmol/L) blocked the anticipated enhancement of RhoA translocation in response to stimulation with Ang II (n=6) ( Figure 3C ).
Results
RhoGEFs gene expression after
Knockdown of LARG decreased RhoA activity
To determine whether LARG gene expression was associated with RhoA activity, we knocked down LARG using siRNA. As expected, LARG mRNA was significantly reduced in the LARG siRNA pretreatment group and in the LARG siRNA pretreatment plus Ang II stimulation (0.1 µmol/L) group (n=6) ( Figure 3D ). LARG proteins were also significantly decreased in the LARG siRNA pretreatment group and in the LARG siRNA plus Val5 (1 µmol/L) group (n=6) ( Figure 3E ). The effect of LARG knockdown on RhoA activity was assessed by an absorbance-based G-LISA™ assay kit. RhoA activity was significantly suppressed in the LARG siRNA pretreatment group and in the LARG siRNA plus Val5 group (n=6) ( Figure  3F ). This finding is consistent with the hypothesis that LARG acts upstream of the RhoA signaling pathway.
AT 1 activation enhanced MYPT1 phosphorylation
The phosphorylation of MYPT1 at Thr 696 (phospho-MYPT1) in VSMCs was measured prior to stimulation (0 h group) and after stimulation with Val5 (1 µmol/L) or Ang II (0.1 µmol/L) plus PD123319 (1 µmol/L) at 3, 6, and 9 h (Figure 4A  & 4B) . The results showed that MYPT1 phosphorylation was enhanced after AT 1 activation, with the phosphorylation of MYPT1 consistently increasing over 9 h (n=6).
Knockdown of LARG decreases MYPT1 phosphorylation LARG knockdown was utilized to determine whether LARG gene expression is associated with MYPT1 phosphorylation. Rat VSMCs were transfected with LARG siRNA or scrambled siRNA. After 36 h, the cells were treated with or without Val5 (1 µmol/L) for three or nine hours and harvested. LARG silenced cells showed a markedly decreased MYPT1 Pretreatment with LARG siRNA diminishes Ang II-induced vasoconstriction Aortic rings were transfected with scrambled siRNA or LARG siRNA for 48 h. Protein was extracted from each rat aortic ring and subjected to Western blot analysis to verify the efficiency of LARG knockdown ( Figure 5A ). The remaining Figure  5B1 shows a typical curve for Ang II-induced contraction of rat aortic rings. The antagonists evaluated included the AT 2 antagonist PD123319 (1 µmol/L) and the AT 1 antagonist losartan (1 µmol/L), as shown in Figure 5B2 and 5B3, respectively. We examined the effects of siRNA against LARG on the contraction of rat aortic rings in response to Ang II to clarify the role of LARG in Ang II/Ca 2+ -sensitization signaling of a large conduit artery ( Figure 5B4 ). We found that the force of contraction was weakened in the LARG siRNA pretreated aortic rings in response to Ang II treatment compared to the contractile force of the scrambled-siRNA-treated controls Figure 5B1 , 5B3, and 5C). After completion of the contractile tension recording experiments, the aortic rings were subjected to protein extraction and Western blot analysis to re-confirm the effect of LARG knockdown ( Figure 5D ).
Discussion
This study provides direct evidence that the activation of AT 1 enhances LARG gene expression, which increases RhoA activity and MYPT1 phosphorylation, leading to inactivation of MLCP and the promotion of Ca 2+ sensitization in VSMCs. These effects result in VSMCs contraction and vasoconstriction. Knockdown of LARG by siRNA decreased aortic ring contraction in response to Ang II stimulation. The results confirm that MLCP phosphorylation is directly regulated by LARG gene expression that occurs in response to AT 1 activation.
We found that LARG acts upstream of the RhoA/Rho kinase pathway. By contrast, p115-RhoGEF and PDZ-RhoGEF, which exhibit trends similar to LARG following AT 1 activa- [26] . Aortae are composed of multiple tissue types; in addition to smooth muscle, they also contain connective tissue and fibroblasts. In this study, we used primary cultured VSMCs to eliminate the interference of signaling from different cell types. Ying et al showed that Ang II transiently upregulates LARG mRNA and increases Y27632-induced vasodilation in Ang II-incubated rat aortic rings [14] . Our findings support Ying's results.
VSMC contraction is dependent on the extent of MLC phosphorylation, which is regulated by the balance between Ca 2+ -dependent MLCK and Ca 2+ -independent MLCP activities [7, 27] . Therefore, the regulation of MLCP activity by the phosphorylation of MYPT1 plays a critical role in Ang II-induced, Ca 2+ -independent, Ca 2+ sensitization of VSMCs. Most studies investigating the calcium sensitization pathway in VSMCs either report RhoA activity or estimate vasorelaxation induced by Rho kinase inhibition [14] . However, Rho-kinase is a point of divergence for multiple signal pathways, and thus, Rho kinase mobility is not solely responsible for the Ca 2+ -sensitization of myofilaments. Because Rho-kinase induced phosphorylation of MLC occurs via phosphorylation of the MYPT1 on MLCP, a better method to identify the Ca 2+ sensitivity of VSMCs might be to assess the phosphorylation of MYPT1.
Guilluy et al showed that MYPT1 phosphorylation levels are decreased in the aortic smooth muscle cells in p115-RhoGEF deficient mice treated with Ang II [8] . Another study showed that the Gα 12 Gα 13 /LARG pathway is crucial to saltinduced hypertension [17] . However, it has not been directly demonstrated that AT 1 activated LARG gene expression regulates the phosphorylation of MYPT-1. Our results illustrate that the increased LARG protein expression that results from AT 1 activation contributes to the enhancement of MYPT1 phosphorylation. Our ex vivo data also indicate that the specific knockdown of LARG in aortic rings results in a diminished contractile force in response to Ang II. Hypertension increases arterial tone in both small resistance arteries (myogenic tone) and large conduit arteries (spontaneous tone). It has also been established that RhoA signaling mediates the development of spontaneous tone in Ang II-induced hypertensive rats [4] . Our current findings may aid the elucidation of the mechanism involved in controlling spontaneous tone in the vascular wall of large conduit arteries.
The transient increase of LARG mRNA at 0.5 h in response to Ang II stimulation and its subsequent disappearance after 3 h is due to the short duration of Ang II stimulation and the decay of Ang II. In addition, LARG mRNA may be digested by RNase activity. LARG mRNA expression, in vivo, may be related to the continuous stimulation of intravascular Ang II, which is different from our in vitro observations. The physiological relevance of LARG expression is to maintain vascular tone by causing sustained contraction.
Our study has some limitations. Ang II-induced VSMC contraction is both calcium dependent and calcium independent (calcium sensitization). We use the same concentration of Ang II to stimulate VSMC in all of the independent experiments. Thus, the calcium-dependent pathway is purported to function the same when contributing to VSMC contraction. We only focused our studies on the calcium sensitization pathway, and we did not measure the intracellular calcium concentration. Protein kinase C (PKC) and its downstream target CPI-17, a 17 kDa PKCpotentiated inhibitor protein, is another potential mediator of Ca 2+ sensitization. The activation of CPI-17, via the phosphorylation by PKC, inhibits the MLCP catalytic subunit PP 1C [27, 28] . We did not study the role of PKC or CPI-17 in LARG expression or the association of LARG protein with Ca 2+ sensitization in VSMCs. These topics warrant further investigation.
In conclusion, the LARG/RhoA-Rho kinase/MYPT1 signaling pathway is identified as the predominant pathway involved in the Ca 2+ sensitization of myofilaments. This signaling pathway responds to AT 1 -induced Ca 2+ sensitivity in VSMCs. Stimulation of AT 1 increases LARG protein expression, the extent of membrane localization of RhoA (active RhoA), and the phosphorylation of MYPT1.
